Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Scleroderma renal crisis

V D Steen1

  • 1Division of Rheumatology, Immunology, and Allergy, Georgetown University Medical Center, Washington, DC 20007-2197, USA.

Rheumatic Diseases Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SYSTEMIC SCLEROSIS RELATED CALCINOSIS: PATIENTS PROVIDE WHAT SPECIALISTS WANT TO LEARN.

The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society·2016
Same author

Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters.

Clinical and experimental rheumatology·2014
Same author

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative.

Clinical and experimental rheumatology·2013
Same author

Is exercise-induced pulmonary hypertension ready for prime time in systemic sclerosis?

International journal of clinical practice. Supplement·2010
Same author

Development of a provisional core set of response measures for clinical trials of systemic sclerosis.

Annals of the rheumatic diseases·2007
Same author

Minimally important difference in diffuse systemic sclerosis: results from the D-penicillamine study.

Annals of the rheumatic diseases·2006
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Systemic sclerosis patients experiencing renal crisis, marked by severe hypertension and kidney failure, now have improved outcomes. Early treatment with angiotensin-converting enzyme (ACE) inhibitors significantly enhances survival and reduces dialysis dependency.

Area of Science:

  • Nephrology
  • Rheumatology
  • Internal Medicine

Background:

  • Systemic sclerosis (SSc) can lead to a life-threatening renal crisis.
  • This complication is characterized by malignant hypertension, hyperreninemia, azotemia, and microangiopathic hemolytic anemia.
  • Historically, SSc renal crisis had a poor prognosis.

Purpose of the Study:

  • To highlight the effectiveness of angiotensin-converting enzyme (ACE) inhibitors in treating SSc renal crisis.
  • To emphasize the importance of prompt diagnosis and early intervention.
  • To discuss the impact of ACE inhibitors on patient survival and renal function.

Main Methods:

  • Review of clinical data and treatment outcomes for SSc patients with renal crisis.
  • Analysis of the role of ACE inhibitors in managing hypertension and renal function.

Related Experiment Videos

  • Comparison of outcomes before and after the introduction of ACE inhibitor therapy.

    • Main Results:

    • ACE inhibitors have transformed the prognosis of SSc renal crisis, with most patients now responding successfully.
    • Therapy with ACE inhibitors improves survival rates and reduces the need for dialysis.
    • Many patients on dialysis have been able to discontinue the procedure after 6-18 months of ACE inhibitor treatment.

    Conclusions:

    • Prompt diagnosis and aggressive early treatment with ACE inhibitors are crucial for optimal outcomes in SSc renal crisis.
    • ACE inhibitors are the cornerstone of modern management for this condition.
    • Chronic non-crisis renal insufficiency in SSc is uncommon and typically does not lead to severe renal dysfunction.